Phosphodiesterase 5 inhibitor mirodenafil ameliorates alzheimer-like pathology and symptoms by multimodal actions

HIGHLIGHTS

• who: Byung Woo Kang from the Seongnam‑si, Gyeonggi‑do, Republic of Korea have published the research: Phosphodiesterase 5 inhibitor mirodenafil ameliorates Alzheimer-like pathology and symptoms by multimodal actions, in the Journal: (JOURNAL)
• what: The authors investigated the mechanisms of action that underlie the beneficial disease-modifying effects of mirodenafil against Aβ-induced pathology using both in_vitro and in_vivo AD mouse models. The authors report that mirodenafil exerts neuroprotective effects against cognitive dysfunction and AD pathophysiology through multiple mechanisms of action involving the reduction of Aβ and phosphorylated tau burdens, enhanced neuronal survival through . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.